Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Liu, M.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
Stanford UniversityBA06/1999Economics
Stanford UniversityMS03/2001Computer Science
Johns Hopkins School of Public HealthMPH06/2010Biostatistics and Epidemiology
Johns Hopkins University School of MedicineMD05/2011Medicine
Johns Hopkins Hospital06/2014Internal Medicine Residency
Dana-Farber Cancer Institute/Harvard CancerCare08/2018Hematology/Oncology Fellowship
2002 - 2004
Amazon.com Innovation Awards (x3), US Patent 7,536,322
2010
JHSPH MPH Capstone Award
2012
JHUSOM Medical Student Teaching Award
2015
John R. Svenson Fellowship in Genomic Research
2018
Damon Runyon Physician-Scientist Training Grant
2018
ASCO Young Investigator Award
2018
SITC Cancer Immunotherapy Translational Fellowship
2019
AACR NextGen Stars
2020
ASCI Young Physician-Scientist

Overview
Dr. Liu is a medical oncologist and computational biologist at the Dana-Farber Cancer Institute and Brigham & Women's Hospital, with a background in computer science, biostatistics, and epidemiology. The Liu lab bridges multiple disciplines, and operates at the intersection of clinical oncology, cancer biology, and computational biology, developing computational approaches to dissect therapeutic resistance and susceptibility to chemo-, targeted-, and immuno-therapies in patient tumors. A focus is on development of rigorous methodologies using statistics and machine-learning techniques applied to specific clinical contexts to discover biologically relevant molecular correlates of response/resistance (for novel therapeutic targets and rational combination therapies) and build clinically relevant predictive models of therapeutic response/resistance. Examples of past work include

(1) development of predictive models of response to PD-1 immune checkpoint blockade in metastatic melanoma integrating clinical, genomic, and transcriptomic features (Liu, Schilling et al Nat Medicine 2019)
(2) validation of mutations in ERCC2 (gene necessary for nucleotide excision DNA repair) as marker of susceptibility to cisplatin-based chemotherapy in muscle-invasive bladder cancer, leading to clinical trials in progress (Liu et al JAMA Onc 2016; Li et al Clin Canc Res 2019)
(3) discovering a novel class of chromatin-modulating gene mutations as drivers of oncogenesis in a standardized meta-analysis of over 1000 prostate cancers (Armenia*, Wankowic*, Liu* et al Nat Gen 2018) *co-first author
(4) de novo discovery of a cisplatin-induced mutational signature in pre- and post-cisplatin treated bladder cancers, later validated in platinum-treated lung and ovarian cancers (Liu et al Nat Comm 2017)
(5) in the same cohort, discovery of intratumoral heterogeneity and multiple gene mutations as molecular correlates of survival and therapeutic resistance (Liu et al Nat Comm 2017)
(6) dissection of immunological correlates to a signature of mismatch repair deficiency in prostate cancer (Nava Rodrigues*, Rescigno*, Liu* et al JCI 2018) *co-first author
(7) elucidating evolution of therapeutic resistance and tumor heterogeneity from 23 tumor samples from a melanoma delayed exceptional responder to sequential immune checkpoint blockade collected over 6 years (Liu et al, under review)

Two broad areas of inquiry exist in the lab:

1. Development of parsimonious, biologically-informed predictive models utilizing statistical and machine learning approaches and integrating clinical and molecular data to guide clinical management.

2. Mapping of clinical tumor heterogeneity and evolution of resistance and metastasis, using longitudinally collected tumor samples from patients over time, treatments, development of resistance, and from different metastatic sites to develop insight into drivers of resistance and metastasis.

Current list of publications:
https://www.ncbi.nlm.nih.gov/myncbi/david.liu.4/bibliography/public/

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. (BOLAND, GENEVIEVE) Mar 1, 2019 - Feb 28, 2021
    Melanoma Research Foundation
    Characterizing the Role of the Hippo Pathway during Melanoma Immunotherapy
    Role: Co-Investigator
  2. K08CA234458 (LIU, DAVID) Sep 18, 2018 - Aug 31, 2023
    NIH
    Dissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational Oncology
    Role: Principal Investigator
  3. (LIU, DAVID) Jul 1, 2018 - Jun 30, 2020
    Society for Immunotherapy of Cancer - BMS
    Dissecting Differential Response to Immunotherapy in Melanoma through Clinical Computational Oncology
    Role: Principal Investigator
  4. (LIU, DAVID) Jul 1, 2018 - Jun 30, 2019
    Conquer Cancer Foundation/ASCO
    Dissecting Response and Resistance to Immune and Targeted Therapies in Metastatic Melanoma Through Clinical Computational Oncology
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Such L, Zhao F, Liu D, Thier B, Le-Trilling VTK, Sucker A, Coch C, Pieper N, Howe S, Bhat H, Kalkavan H, Ritter C, Brinkhaus R, Ugurel S, Köster J, Seifert U, Dittmer U, Schuler M, Lang KS, Kufer TA, Hartmann G, Becker JC, Horn S, Ferrone S, Liu D, Van Allen EM, Schadendorf D, Griewank K, Trilling M, Paschen A. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. J Clin Invest. 2020 Aug 03; 130(8):4266-4281. PMID: 32427578.
    Citations:    
  2. Reidenbach AG, Mesleh MF, Casalena D, Vallabh SM, Dahlin JL, Leed AJ, Chan AI, Usanov DL, Yehl JB, Lemke CT, Campbell AJ, Shah RN, Shrestha OK, Sacher JR, Rangel VL, Moroco JA, Sathappa M, Nonato MC, Nguyen KT, Wright SK, Liu DR, Wagner FF, Kaushik VK, Auld DS, Schreiber SL, Minikel EV. Multimodal small-molecule screening for human prion protein binders. J Biol Chem. 2020 Jul 28. PMID: 32723867.
    Citations:    
  3. Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, Hsu F, Radey MC, Peterson SB, Mootha VK, Mougous JD, Liu DR. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020 Jul; 583(7817):631-637. PMID: 32641830.
    Citations:    
  4. Richter MF, Zhao KT, Eton E, Lapinaite A, Newby GA, Thuronyi BW, Wilson C, Koblan LW, Zeng J, Bauer DE, Doudna JA, Liu DR. Author Correction: Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol. 2020 Jul; 38(7):901. PMID: 32433548.
    Citations:    
  5. Wilson C, Chen PJ, Miao Z, Liu DR. Programmable m6A modification of cellular RNAs with a Cas13-directed methyltransferase. Nat Biotechnol. 2020 Jun 29. PMID: 32601430.
    Citations:    
  6. Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020 Jul; 38(7):824-844. PMID: 32572269.
    Citations:    
  7. Arbab M, Shen MW, Mok B, Wilson C, Matuszek Z, Cassa CA, Liu DR. Determinants of Base Editing Outcomes from Target Library Analysis and Machine Learning. Cell. 2020 Jul 23; 182(2):463-480.e30. PMID: 32533916.
    Citations:    
  8. Yeh WH, Shubina-Oleinik O, Levy JM, Pan B, Newby GA, Wornow M, Burt R, Chen JC, Holt JR, Liu DR. In vivo base editing restores sensory transduction and transiently improves auditory function in a mouse model of recessive deafness. Sci Transl Med. 2020 Jun 03; 12(546). PMID: 32493795.
    Citations:    
  9. Morrison MS, Podracky CJ, Liu DR. The developing toolkit of continuous directed evolution. Nat Chem Biol. 2020 Jun; 16(6):610-619. PMID: 32444838.
    Citations:    
  10. Davis JC, Alves TC, Helman A, Chen JC, Kenty JH, Cardone RL, Liu DR, Kibbey RG, Melton DA. Glucose Response by Stem Cell-Derived ß Cells In Vitro Is Inhibited by a Bottleneck in Glycolysis. Cell Rep. 2020 May 12; 31(6):107623. PMID: 32402282.
    Citations:    
  11. Gstalder C, Liu D, Miao D, Lutterbach B, DeVine AL, Lin C, Shettigar M, Pancholi P, Buchbinder EI, Carter SL, Manos MP, Rojas-Rudilla V, Brennick R, Gjini E, Chen PH, Lako A, Rodig S, Yoon CH, Freeman GJ, Barbie DA, Hodi FS, Miles W, Van Allen EM, Haq R. Inactivation of Fbxw7 impairs dsRNA sensing and confers resistance to PD-1 blockade. Cancer Discov. 2020 May 05. PMID: 32371478.
    Citations:    
  12. Richter MF, Zhao KT, Eton E, Lapinaite A, Newby GA, Thuronyi BW, Wilson C, Koblan LW, Zeng J, Bauer DE, Doudna JA, Liu DR. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol. 2020 Jul; 38(7):883-891. PMID: 32433547.
    Citations:    
  13. Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, Ricker C, Kochupurakkal BS, Choudhury AD, Hahn WC, Balk SP, Hwang JH, Van Allen EM, Mouw KW. ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 2020 Jun 01; 80(11):2094-2100. PMID: 32127357.
    Citations:    
  14. Dietlein F, Weghorn D, Taylor-Weiner A, Richters A, Reardon B, Liu D, Lander ES, Van Allen EM, Sunyaev SR. Identification of cancer driver genes based on nucleotide context. Nat Genet. 2020 02; 52(2):208-218. PMID: 32015527.
    Citations:    
  15. Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019 12; 25(12):1916-1927. PMID: 31792460.
    Citations:    
  16. Hwang JH, Seo JH, Beshiri ML, Wankowicz S, Liu D, Cheung A, Li J, Qiu X, Hong AL, Botta G, Golumb L, Richter C, So J, Sandoval GJ, Giacomelli AO, Ly SH, Han C, Dai C, Pakula H, Sheahan A, Piccioni F, Gjoerup O, Loda M, Sowalsky AG, Ellis L, Long H, Root DE, Kelly K, Van Allen EM, Freedman ML, Choudhury AD, Hahn WC. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019 11 19; 29(8):2355-2370.e6. PMID: 31747605.
    Citations:    
  17. Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3. PMID: 31832578.
    Citations:    
  18. Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, Van Seventer EE, Tracy A, Wo JY, Carter SL, Willers H, Corcoran RB, Hong TS, Van Allen EM. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clin Cancer Res. 2019 09 15; 25(18):5561-5571. PMID: 31253631.
    Citations:    
  19. Gurjao C, Liu D, Hofree M, AlDubayan SH, Wakiro I, Su MJ, Felt K, Gjini E, Brais LK, Rotem A, Rosenthal MH, Rozenblatt-Rosen O, Rodig S, Ng K, Van Allen EM, Corsello SM, Ogino S, Regev A, Nowak JA, Giannakis M. Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. Cancer Immunol Res. 2019 08; 7(8):1230-1236. PMID: 31217164.
    Citations:    
  20. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411. PMID: 30990729.
    Citations:    
  21. Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, Dimopoulos MA. Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Hematol. 2019 05; 94(5):E146-E149. PMID: 30773670.
    Citations:    
  22. Liu D, Jenkins RW, Sullivan RJ. Mechanisms of Resistance to Immune Checkpoint Blockade. Am J Clin Dermatol. 2019 Feb; 20(1):41-54. PMID: 30259383.
    Citations:    Fields:    
  23. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. PMID: 30388455.
    Citations:    Fields:    
  24. Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 10 01; 128(10):4441-4453. PMID: 30179225.
    Citations:    Fields:    
  25. Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281. PMID: 30150660.
    Citations:    Fields:    
  26. Li Q, Damish AW, Frazier Z, Liu D, Reznichenko E, Kamburov A, Bell A, Zhao H, Jordan EJ, Gao SP, Ma J, Abbosh PH, Bellmunt J, Plimack ER, Lazaro JB, Solit DB, Bajorin D, Rosenberg JE, D'Andrea AD, Riaz N, Van Allen EM, Iyer G, Mouw KW. ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2019 02 01; 25(3):977-988. PMID: 29980530.
    Citations:    Fields:    
  27. Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM, Schultz N, Van Allen EM. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 05; 50(5):645-651. PMID: 29610475.
    Citations: 10     Fields:    
  28. Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discov. 2018 04; 8(4):417-427. PMID: 29431697.
    Citations: 3     Fields:    
  29. Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, Chen DYT, Alpaugh RK, Hoffman-Censits J, Garraway LA, Getz G, Carter SL, Bellmunt J, Plimack ER, Rosenberg JE, Van Allen EM. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017 12 19; 8(1):2193. PMID: 29259186.
    Citations: 2     Fields:    Translation:HumansCells
  30. Liu D, Vokes NI, Van Allen EM. Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. Cancer Discov. 2017 06; 7(6):555-557. PMID: 28576842.
    Citations: 1     Fields:    Translation:Humans
  31. Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016 Aug 01; 2(8):1094-6. PMID: 27310333.
    Citations: 22     Fields:    Translation:Humans
  32. Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, Oliver N, MacConaill L, Ducar M, Rojas-Rudilla V, Giannakis M, Ghazani A, Gray S, Janne P, Garber J, Joffe S, Lindeman N, Wagle N, Garraway LA, Van Allen EM. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016 07 26; 8(1):79. PMID: 27460824.
    Citations: 15     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Liu's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (105)
Explore
_
Co-Authors (102)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.